AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 312 min read$TEM

LEFKOFSKY ERIC P sold $10.5M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 250,000 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $42.06 ($41.34–$42.95, $10.51M total) across 12 trades on 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Jul 31, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest actionable element is the disclosed sale size ($10.51M) and post-transaction holdings (200,000 shares). The 10b5-1 designation suggests the trades were scheduled in advance, which typically dampens inference about near-term fundamentals.

02

Market read

This is a primary insider-selling disclosure that may influence short-term sentiment, but it is less likely to drive a fundamental repricing due to the pre-arranged 10b5-1 plan.

03

What to watch

Traders may over-weight insider sales; the key nuance is that the plan was pre-arranged, and the filing does not provide new operational or financial guidance.

Relevance 6/10Novelty 5/10Timing: filed 2026-07-30 for a 2026-07-28 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM) by CEO and Chairman Eric P. Lefkofsky, with the sale executed across multiple trades on 2026-07-28.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO and Chairman sold $10.51M of TEM shares via a 10b5-1 plan, leaving 200,000 shares after the sale.

Expected impact

Low to modest near-term sentiment impact; directionally mixed and likely limited given 10b5-1 pre-arrangement.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size ($10.5M) and timing (2026-07-28), but it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretability as new negative information.

Market effects

Sector

Limited sector read-through; this is company-specific insider selling rather than a sector-wide regulatory or demand signal.

Regional

No clear regional spillover indicated by the filing details.

Global

No global market linkage beyond Tempus AI-specific sentiment.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity planning rather than bearish expectations, so price impact could be negligible.

Key entities

  • issuer
    Tempus AI, Inc.

    Subject of the Form 4 insider transaction; CEO and Chairman sold shares under a 10b5-1 plan.

  • insider
    LEFKOFSKY ERIC P

    CEO and Chairman, reported indirect open-market sale totaling $10.51M across 12 trades.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEM insider trading history →

Related articles

OCT 26
$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

finance.yahoo.com2 min
OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min